Palvella Therapeutics (PVLA) EBITDA (2013 - 2026)
Palvella Therapeutics (PVLA) reported EBITDA of -$15.8 million for Q1 2026, down 92.35% year-over-year from -$205.8 million in Q1 2025, and down 23.71% on a QoQ basis from -$12.7 million in Q4 2025.
Palvella Therapeutics (PVLA) has 14 years of EBITDA data on file, last reported at -$15.8 million in Q1 2026.
- Quarterly EBITDA fell 92.35% year-over-year to -$15.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$49.2 million (down 114.92% YoY) and the FY2025 annual result came in at -$41.6 million, down 138.86% from the prior year.
- EBITDA retreated to -$15.8 million in Q1 2026 per PVLA's latest filing, from -$12.7 million in the prior quarter.
- Across five years, EBITDA topped out at $38.0 million in Q4 2023 and bottomed at -$15.8 million in Q1 2026.
- The 5-year median for EBITDA is -$8.9 million (2025), against an average of -$5.1 million.
- The widest annual swing landed in 2023, when EBITDA soared 139.99%; it then plunged 278.34% in 2025.
- Tracing PVLA's EBITDA over 5 years: stood at -$9.8 million in 2022, then surged by 485.88% to $38.0 million in 2023, then slumped by 108.87% to -$3.4 million in 2024, then sank by 278.34% to -$12.7 million in 2025, then fell by 23.71% to -$15.8 million in 2026.
- Per Business Quant, the three latest PVLA EBITDA figures stand at -$15.8 million (Q1 2026), -$12.7 million (Q4 2025), and -$11.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -13.63 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.44 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 661.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 201.19 Mn |
| 10 | Palvella Therapeutics | 1.47 Bn | 1.21 Bn | - | -15.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15.76 Mn |
| Dec 31, 2025 | -12.74 Mn |
| Sep 30, 2025 | -11.13 Mn |
| Jun 30, 2025 | -9.58 Mn |
| Mar 31, 2025 | -8.19 Mn |
| Dec 31, 2024 | -3.37 Mn |
| Sep 30, 2024 | -6.97 Mn |
| Jun 30, 2024 | -4.37 Mn |
| Mar 31, 2024 | -2.73 Mn |
| Dec 31, 2023 | 37.96 Mn |
| Sep 30, 2023 | -10.95 Mn |
| Jun 30, 2023 | 4.27 Mn |
| Mar 31, 2023 | -13.36 Mn |
| Sep 30, 2022 | -9.84 Mn |
| Jun 30, 2022 | -10.67 Mn |
| Mar 31, 2022 | -4.98 Mn |
| Dec 31, 2021 | -9.32 Mn |
| Sep 30, 2021 | -16.15 Mn |
| Jun 30, 2021 | -15.46 Mn |
| Mar 31, 2021 | -3.68 Mn |
| Dec 31, 2020 | -13.91 Mn |
| Sep 30, 2020 | -14.00 Mn |
| Jun 30, 2020 | -4.79 Mn |
| Mar 31, 2020 | -2.83 Mn |
| Dec 31, 2019 | -2.07 Mn |
| Sep 30, 2019 | -582,000.00 |
| Jun 30, 2019 | -12.41 Mn |
| Mar 31, 2019 | -9.42 Mn |
| Dec 31, 2018 | -11.61 Mn |
| Sep 30, 2018 | -6.63 Mn |
| Jun 30, 2018 | 3.20 Mn |
| Mar 31, 2018 | -9.99 Mn |
| Dec 31, 2017 | 5.28 Mn |
| Sep 30, 2017 | -7.45 Mn |
| Jun 30, 2017 | -10.73 Mn |
| Mar 31, 2017 | -7.94 Mn |
| Dec 31, 2016 | -6.40 Mn |
| Sep 30, 2016 | -6.18 Mn |
| Jun 30, 2016 | -5.80 Mn |
| Mar 31, 2016 | -4.38 Mn |
| Dec 31, 2015 | -2.57 Mn |
| Sep 30, 2015 | -3.88 Mn |
| Jun 30, 2015 | -3.53 Mn |
| Mar 31, 2015 | -3.70 Mn |
| Sep 30, 2014 | -1.84 Mn |
| Jun 30, 2014 | -2.77 Mn |
| Mar 31, 2014 | -671,217.00 |
| Dec 31, 2013 | -2,198.00 |
| Sep 30, 2013 | -5,762.00 |
| Jun 30, 2013 | -274.00 |